<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="128346">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01431326</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00029638</org_study_id>
    <secondary_id>IND 113645</secondary_id>
    <secondary_id>IND 114369</secondary_id>
    <secondary_id>IND 114531</secondary_id>
    <secondary_id>IND 114892</secondary_id>
    <secondary_id>IND 115226</secondary_id>
    <secondary_id>IND 118329</secondary_id>
    <secondary_id>IND 118358</secondary_id>
    <secondary_id>HHSN20100006</secondary_id>
    <secondary_id>HHSN27500020</secondary_id>
    <secondary_id>HHSN27500027</secondary_id>
    <secondary_id>HHSN27500043</secondary_id>
    <nct_id>NCT01431326</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care</brief_title>
  <acronym>PTN_POPS</acronym>
  <official_title>Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel Benjamin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The EMMES Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>OpAns, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Understudied drugs will be administered to children per standard of care as prescribed by
      their treating caregiver and only biological sample collection during the time of drug
      administration will be involved. A total of approximately 3000 children aged &lt;21 years who
      are receiving these drugs for standard of care will be enrolled and will be followed for up
      a maximum of 90 days. The goal of this study is to characterize the pharmacokinetics of
      understudied drugs for which specific dosing recommendations and safety data are lacking.
      The prescribing of drugs to children will not be part of this protocol. Taking advantage of
      procedures done as part of routine medical care (i.e. blood draws) this study will serve as
      a tool to better understand drug exposure in children receiving these drugs per standard of
      care. The data collected through this initiative will also provide valuable pharmacokinetic
      and dosing information of drugs in different pediatric age groups as well as special
      pediatric populations (i.e. obese).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to characterize the PK ( Pharmacokinetics) of understudied
      drugs administered to children per standard of care as prescribed by their treating
      caregiver. This will be accomplished by the collection of biological samples during the time
      of drug administration per standard of care as prescribed by the caregiver. The prescribing
      of drugs to children will not be part of this protocol.

      Aim #1: Evaluate the PK of understudied drugs currently being administered to children.

      Hypothesis #1: The PK of understudied drugs in children will differ from adults and within
      children according to pediatric age groups or special population.

      Aim #2: Explore the pharmacodynamics (PD) of understudied drugs currently being administered
      to children.

      Hypothesis #2: The PD of targeted drugs in children will differ from adults.

      Aim #3: Evaluate the influence of genetic factors, metabolic and protein profiles on
      therapeutic exposure.

      Hypothesis #3: Genetic polymorphisms in drug metabolizing enzymes and metabolic and
      proteomic profiles will impact drug exposure in children.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of pharmacokinetic outcomes for understudied drugs in children</measure>
    <time_frame>Data will be collected throughout the hospital or outpatient stay up to 90 days</time_frame>
    <description>As appropriate for each study drug, the following additional PK parameters will be estimated:
maximum concentration (Cmax)
time to achieve maximum concentration (Tmax)
absorption rate constant (ka)
elimination rate constant (kel)
half-life (t1/2)
area under the curve (AUC)
Penetration into body fluids will be determined by comparing exposure (i.e. AUC, Cmax) ratios between the body fluid and plasma or comparison of concentrations in paired samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite pharmacodynamic outcomes of understudied drugs in children</measure>
    <time_frame>Data will be collected throughout the hospital or outpatient stay up to 90 days</time_frame>
    <description>When applicable, Monte Carlo simulations will be performed to evaluate therapeutic target attainment rates (pharmacodynamics) in the population of interest. The final PK model and parameters estimated in the population PK analysis will be used to perform these simulations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers associated with understudied drugs in children</measure>
    <time_frame>Data will be collected throughout the hospital or outpatient stay up to 90 days</time_frame>
    <description>The dosing, sampling, and demographic information recorded on the eCRF will be merged with the bioanalytical information to create a biomarker dataset for each study drug. Biomarkers will be identified using metabolomics/proteomics and pharmacogenomics methodologies. Samples for biomarker analysis will be stored for future use in a PTN designated biorepository. Associations between biomarkers and drug exposure will be explored by visual inspection (i.e. scatter plots) and statistical comparisons as needed.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Adenovirus</condition>
  <condition>Adrenal Insufficiency</condition>
  <condition>Airway Swelling</condition>
  <condition>Anesthesia</condition>
  <condition>Anxiety</condition>
  <condition>Anxiolysis</condition>
  <condition>Autism</condition>
  <condition>Autistic Disorder</condition>
  <condition>Bacterial Meningitis</condition>
  <condition>Bacterial Septicemia</condition>
  <condition>Benzodiazepine</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Bone and Joint Infections</condition>
  <condition>Brain Swelling</condition>
  <condition>Central Nervous System Infections</condition>
  <condition>Convulsions</condition>
  <condition>Cytomegalovirus Retinitis</condition>
  <condition>Early-onset Schizophrenia Spectrum Disorders</condition>
  <condition>Edema</condition>
  <condition>Epilepsy</condition>
  <condition>General Anesthesia</condition>
  <condition>Gynecologic Infections</condition>
  <condition>Headaches</condition>
  <condition>Herpes Simplex Virus</condition>
  <condition>Hypertension</condition>
  <condition>Infantile Hemangioma</condition>
  <condition>Infection</condition>
  <condition>Inflammation</condition>
  <condition>Inflammatory Conditions</condition>
  <condition>Influenza</condition>
  <condition>Intra-abdominal Infections</condition>
  <condition>Lower Respiratory Tract Infections</condition>
  <condition>Migraines</condition>
  <condition>Pain</condition>
  <condition>Pneumonia</condition>
  <condition>Prophylaxis</condition>
  <condition>Schizophrenia</condition>
  <condition>Sedation</condition>
  <condition>Seizures</condition>
  <condition>Skeletal Muscle Spasms</condition>
  <condition>Skin and Skin-structure Infections</condition>
  <condition>Stable Angina</condition>
  <condition>Thromboprophylaxis</condition>
  <condition>Thrombosis</condition>
  <condition>Treatment-resistant Schizophrenia</condition>
  <condition>Urinary Tract Infection</condition>
  <condition>Withdrawal</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:</intervention_name>
    <other_name>aripiprazole</other_name>
    <other_name>ceftazidime</other_name>
    <other_name>cidofovir</other_name>
    <other_name>ciprofloxacin</other_name>
    <other_name>dexamethasone</other_name>
    <other_name>diazepam</other_name>
    <other_name>levetiracetam</other_name>
    <other_name>meropenem</other_name>
    <other_name>methylprednisolone</other_name>
    <other_name>midazolam</other_name>
    <other_name>nicardipine</other_name>
    <other_name>olanzapine</other_name>
    <other_name>oseltamivir</other_name>
    <other_name>oxycarbazepine</other_name>
    <other_name>phosphenytoin</other_name>
    <other_name>quetiapine</other_name>
    <other_name>risperidone</other_name>
    <other_name>timolol</other_name>
    <other_name>topiramate</other_name>
    <other_name>valproic acid</other_name>
    <other_name>tobramycin</other_name>
    <other_name>alfentanil</other_name>
    <other_name>clozapine</other_name>
    <other_name>fosphenytoin</other_name>
    <other_name>haloperidol</other_name>
    <other_name>heparin (low molecular weight)</other_name>
    <other_name>hydromorphone</other_name>
    <other_name>lurasidone</other_name>
    <other_name>molindone</other_name>
    <other_name>morphine</other_name>
    <other_name>pentobarbital</other_name>
    <other_name>propofol</other_name>
    <other_name>warfarin (oral)</other_name>
    <other_name>ziprasidone</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children (&lt;21 years of age) receiving drugs per standard of care as prescribed by treating
        caregiver
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Children (&lt; 21 years of age) who are receiving understudied drugs of interest per
             standard of care as prescribed by their treating caregiver

        Exclusion Criteria:

          -  1) Failure to obtain consent/assent (as indicated)

          -  2) Known pregnancy as determined via interview or testing if available.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Cohen-Wolkowiez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chiara Melloni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chiara Melloni, MD</last_name>
    <phone>919-668-8646</phone>
    <email>chiara.melloni@dm.duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barrie L Harper, MT (ASCP)</last_name>
    <phone>919-668-8291</phone>
    <email>barrie.harper@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Howard</last_name>
      <phone>501-364-6990</phone>
      <email>howardleee@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Laura James, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at San Diego Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Lang</last_name>
      <phone>310-206-2439</phone>
      <email>elang@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Jaime Deville, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Steinbess</last_name>
      <phone>720-777-3019</phone>
      <email>matthew.steinbess@childrenscolorado.org</email>
    </contact>
    <contact_backup>
      <last_name>Jendar Deschenes</last_name>
      <email>jendar.deschenes@childrenscolorado.org</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Mourani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Children's Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Mulvey</last_name>
      <phone>203-688-2320</phone>
      <email>christine.mulvey@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Bizzarro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred I. DuPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramany John</last_name>
      <phone>302-651-7521</phone>
      <email>ramany.john@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Marisa Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Williams</last_name>
      <phone>202-476-2245</phone>
      <email>efwillia@cnmc.org</email>
    </contact>
    <investigator>
      <last_name>John van den Anker, MD, PhD, FAAP, FCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida Jacksonville Shands Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saniyyah Mahmoudi</last_name>
      <phone>904-244-5031</phone>
      <email>saniyyah.mahmoudi@jax.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Mobeen Rathore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Fearn</last_name>
      <phone>312-227-6285</phone>
      <email>lfearn@luriechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Benjamin Traisman</last_name>
      <email>btraisman@luriechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ram Yogev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children at Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Gunn</last_name>
      <phone>317-278-5239</phone>
      <email>sgunn@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Sokol Gregory, MD,</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wesely Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Delmore</last_name>
      <phone>316-962-8580</phone>
      <email>paula.delmore@wesleymc.com</email>
    </contact>
    <investigator>
      <last_name>Paula Delmore, MSN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Perry</last_name>
      <phone>502-629-5123</phone>
      <email>jacqueline.perry@louisville.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Wiseheart</last_name>
      <phone>502-629-7595</phone>
      <email>mlpatt02@exchange.louisville.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Janice Sullivan, MD, FAAP, FCCM, CPI, CIP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals and Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>UNC Hospital Neonatal-Perinatal Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Bernhardt</last_name>
      <phone>919-843-2373</phone>
      <email>bernhardt@unc.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Laughon, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center (PICU / NICU)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Wrenn</last_name>
      <phone>919-681-2554</phone>
      <email>samantha.wrenn@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christie Milleson</last_name>
      <phone>919-681-2401</phone>
      <email>christie.milleson@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin Watt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hornik Chi, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Terrell</last_name>
      <phone>513-803-3294</phone>
      <email>Tara.Terrell@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Theresa Mottes</last_name>
      <phone>513-803-3296</phone>
      <email>theresa.mottes@cchmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Stuart Goldstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Goldblatt</last_name>
      <phone>216-844-5112</phone>
      <email>eileen.goldblatt@uhhospitals.org</email>
    </contact>
    <contact_backup>
      <last_name>Eloise Lemon</last_name>
      <phone>216-844-3339</phone>
      <email>eloise.lemon@uhhospitals.org</email>
    </contact_backup>
    <investigator>
      <last_name>David Speicher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44313</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201-2701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kira Clark</last_name>
      <phone>503-418-8112</phone>
      <email>clarki@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Connie Swanson</last_name>
      <phone>503-494-2797</phone>
      <email>swansoco@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Amira Al-Uzri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Layla Al-Sarraf</last_name>
      <phone>843-792-5309</phone>
      <email>alsarral@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Infinger</last_name>
      <phone>832-792-7857</phone>
      <email>infinge@musc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Atz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospitals and Clinics</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharada Dixit, RN</last_name>
      <phone>801-587-7525</phone>
      <email>sharada.dixit@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Hina Yazdani</last_name>
      <email>hina.yazdani@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Catherine Sherwin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Children's Hospital</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908-0386</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Kelton-Rehkopf</last_name>
      <phone>206-884-1422</phone>
      <email>megan.keltonr@seattlechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Kathryn Nickel</last_name>
      <phone>206-884-1265</phone>
      <email>kathryn.nickel@seattlechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph Flynn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Mueller</last_name>
      <phone>414-955-2846</phone>
      <email>kamueller@mcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Angela Beltrame</last_name>
      <phone>414-955-2847</phone>
      <email>anbeltrame@mcw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Beth Drolet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manitoba Institute of Child Health</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannine Schellenberg</last_name>
      <phone>1-204-975-7716</phone>
      <email>jschellenberg@mich.ca</email>
    </contact>
    <contact_backup>
      <last_name>Geert T'Jong, MD</last_name>
      <phone>1-204-789-3206</phone>
      <email>gtjong@mich.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Geert T'Jong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angie Tuttle</last_name>
      <phone>613-737-7600</phone>
      <phone_ext>6058</phone_ext>
      <email>atuttle@cheo.on.ca</email>
    </contact>
    <investigator>
      <last_name>Hugh McMillan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maggie Rumantir, MD</last_name>
      <phone>1-416-813-7654</phone>
      <phone_ext>309153</phone_ext>
      <email>maggie.rumantir@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Yaron Finkelstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>T3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Dumitrascu</last_name>
      <phone>1-514-345-4931</phone>
      <phone_ext>6648</phone_ext>
      <email>mariana.dumitrascu@recherche-ste-justine.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Julie Autmizguine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Zerifin</city>
        <state>Tel Aviv</state>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matitiahu Berkovitch, MD</last_name>
      <phone>011-972-8-977-9152</phone>
      <email>mberkovitch@asaf.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Elkana Kohn</last_name>
      <email>elkanak@asaf.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Matitiahu Berkovitch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center of Israel</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nava Mattiyahu</last_name>
      <phone>011-972-3-9253661</phone>
      <email>navama4@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Yehezkel (Hezi) Waisman, MD</last_name>
      <phone>011-972-3-925-3661</phone>
      <email>waisy@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Yehezkel (Hezi) Waisman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KK Women's and Children's Hospital Pte Ltd</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Hau Lee, MD</last_name>
      <phone>1-65-9699-5200</phone>
      <email>lee.jan.hau@kkh.com.sg</email>
    </contact>
    <contact_backup>
      <last_name>Kathy Liaw</last_name>
      <phone>1-65-6394-8939</phone>
      <email>kathy.liaw.cs@kkh.com.sg</email>
    </contact_backup>
    <investigator>
      <last_name>Jan Hau Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danny Pratt</last_name>
      <phone>011-44-0-23-8120-3853</phone>
      <email>danny.pratt@uhs.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Iain Macintosh, MD</last_name>
      <phone>011-44-0-23-8120-8328</phone>
      <email>iain.macintosh@uhs.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Iain Macintosh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Walsh</last_name>
      <phone>011-4401512525570</phone>
      <phone_ext>3552</phone_ext>
      <email>laura.walsh@alderhey.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Dan Hawcutt, MD</last_name>
      <phone>011-44-151-228-4811</phone>
      <phone_ext>2441</phone_ext>
      <email>d.hawcutt@liverpool.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Dan Hawcutt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Bristol</name>
      <address>
        <city>Bristol</city>
        <zip>BS8 1TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clare Harrison</last_name>
      <email>clare.harrison@uhbristol.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Marion Roderick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>Singapore</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pediatrictrials.org/whats-happening-now/studies-in-children/pharmacokinetics-of-understudied-drugs-administered-to-children-per-standard-of-care-ptn-pops</url>
    <description>Understudied Drugs Project Summary</description>
  </link>
  <reference>
    <citation>Wilson JT. An update on the therapeutic orphan. Pediatrics. 1999 Sep;104(3 Pt 2):585-90.</citation>
    <PMID>10469794</PMID>
  </reference>
  <reference>
    <citation>Ceci A, Felisi M, Baiardi P, Bonifazi F, Catapano M, Giaquinto C, Nicolosi A, Sturkenboom M, Neubert A, Wong I. Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years. Eur J Clin Pharmacol. 2006 Nov;62(11):947-52. Epub 2006 Oct 5.</citation>
    <PMID>17021892</PMID>
  </reference>
  <reference>
    <citation>Benjamin DK Jr, Smith PB, Murphy MD, Roberts R, Mathis L, Avant D, Califf RM, Li JS. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA. 2006 Sep 13;296(10):1266-73.</citation>
    <PMID>16968851</PMID>
  </reference>
  <reference>
    <citation>'t Jong GW, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Anker JN. Unapproved and off-label use of drugs in a children's hospital. N Engl J Med. 2000 Oct 12;343(15):1125.</citation>
    <PMID>11032528</PMID>
  </reference>
  <reference>
    <citation>Pullen J, Stolk LM, Nieman FH, Degraeuwe PL, van Tiel FH, Zimmermann LJ. Population pharmacokinetics and dosing of amoxicillin in (pre)term neonates. Ther Drug Monit. 2006 Apr;28(2):226-31.</citation>
    <PMID>16628135</PMID>
  </reference>
  <reference>
    <citation>Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med. 2003 Sep 18;349(12):1157-67. Review.</citation>
    <PMID>13679531</PMID>
  </reference>
  <reference>
    <citation>Fischer S, Bohn D, Rycus P, Pierre AF, de Perrot M, Waddell TK, Keshavjee S. Extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation: analysis of the Extracorporeal Life Support Organization (ELSO) registry. J Heart Lung Transplant. 2007 May;26(5):472-7.</citation>
    <PMID>17449416</PMID>
  </reference>
  <reference>
    <citation>Lequier L. Extracorporeal life support in pediatric and neonatal critical care: a review. J Intensive Care Med. 2004 Sep-Oct;19(5):243-58. Review.</citation>
    <PMID>15358943</PMID>
  </reference>
  <reference>
    <citation>Frenckner B, Radell P. Respiratory failure and extracorporeal membrane oxygenation. Semin Pediatr Surg. 2008 Feb;17(1):34-41. Review.</citation>
    <PMID>18158140</PMID>
  </reference>
  <reference>
    <citation>Rajagopal SK, Almond CS, Laussen PC, Rycus PT, Wypij D, Thiagarajan RR. Extracorporeal membrane oxygenation for the support of infants, children, and young adults with acute myocarditis: a review of the Extracorporeal Life Support Organization registry. Crit Care Med. 2010 Feb;38(2):382-7. doi: 10.1097/CCM.0b013e3181bc8293.</citation>
    <PMID>19789437</PMID>
  </reference>
  <reference>
    <citation>Buck ML. Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clin Pharmacokinet. 2003;42(5):403-17. Review.</citation>
    <PMID>12739981</PMID>
  </reference>
  <reference>
    <citation>Southgate WM, DiPiro JT, Robertson AF. Pharmacokinetics of gentamicin in neonates on extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 1989 Jun;33(6):817-9.</citation>
    <PMID>2764529</PMID>
  </reference>
  <reference>
    <citation>Dodge WF, Jelliffe RW, Zwischenberger JB, Bellanger RA, Hokanson JA, Snodgrass WR. Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation. Ther Drug Monit. 1994 Dec;16(6):552-9.</citation>
    <PMID>7878693</PMID>
  </reference>
  <reference>
    <citation>Bhatt-Mehta V, Johnson CE, Schumacher RE. Gentamicin pharmacokinetics in term neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy. 1992;12(1):28-32.</citation>
    <PMID>1549536</PMID>
  </reference>
  <reference>
    <citation>Munzenberger PJ, Massoud N. Pharmacokinetics of gentamicin in neonatal patients supported with extracorporeal membrane oxygenation. ASAIO Trans. 1991 Jan-Mar;37(1):16-8.</citation>
    <PMID>2012712</PMID>
  </reference>
  <reference>
    <citation>Hoie EB, Swigart SA, Leuschen MP, Willett LD, Bolam DL, Goodrich PD, Bussey ME, Nelson RM Jr. Vancomycin pharmacokinetics in infants undergoing extracorporeal membrane oxygenation. Clin Pharm. 1990 Sep;9(9):711-5.</citation>
    <PMID>2225752</PMID>
  </reference>
  <reference>
    <citation>Buck ML. Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy. 1998 Sep-Oct;18(5):1082-6.</citation>
    <PMID>9758319</PMID>
  </reference>
  <reference>
    <citation>Bhatt-Meht V, Annich G. Sedative clearance during extracorporeal membrane oxygenation. Perfusion. 2005 Oct;20(6):309-15.</citation>
    <PMID>16363315</PMID>
  </reference>
  <reference>
    <citation>Mehta NM, Halwick DR, Dodson BL, Thompson JE, Arnold JH. Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment. Intensive Care Med. 2007 Jun;33(6):1018-24. Epub 2007 Apr 3.</citation>
    <PMID>17404709</PMID>
  </reference>
  <reference>
    <citation>Mulla H, Lawson G, von Anrep C, Burke MD, Upton DU, Firmin RK, Killer H. In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation. Perfusion. 2000 Jan;15(1):21-6.</citation>
    <PMID>10676864</PMID>
  </reference>
  <reference>
    <citation>Poggesi I, Benedetti MS, Whomsley R, Le Lamer S, Molimard M, Watelet JB. Pharmacokinetics in special populations. Drug Metab Rev. 2009;41(3):422-54. doi: 10.1080/10837450902891527. Review.</citation>
    <PMID>19601721</PMID>
  </reference>
  <reference>
    <citation>Buhimschi IA, Buhimschi CS. The role of proteomics in the diagnosis of chorioamnionitis and early-onset neonatal sepsis. Clin Perinatol. 2010 Jun;37(2):355-74. doi: 10.1016/j.clp.2010.03.002. Review.</citation>
    <PMID>20569812</PMID>
  </reference>
  <reference>
    <citation>Bain JR, Stevens RD, Wenner BR, Ilkayeva O, Muoio DM, Newgard CB. Metabolomics applied to diabetes research: moving from information to knowledge. Diabetes. 2009 Nov;58(11):2429-43. doi: 10.2337/db09-0580.</citation>
    <PMID>19875619</PMID>
  </reference>
  <reference>
    <citation>Laiakis EC, Morris GA, Fornace AJ, Howie SR. Metabolomic analysis in severe childhood pneumonia in the Gambia, West Africa: findings from a pilot study. PLoS One. 2010 Sep 9;5(9). pii: e12655. doi: 10.1371/journal.pone.0012655.</citation>
    <PMID>20844590</PMID>
  </reference>
  <reference>
    <citation>Husain A, Loehle JA, Hein DW. Clinical pharmacogenetics in pediatric patients. Pharmacogenomics. 2007 Oct;8(10):1403-11. Review.</citation>
    <PMID>17979513</PMID>
  </reference>
  <results_reference>
    <citation>Phan H, Leder M, Fishley M, Moeller M, Nahata M. Off-label and unlicensed medication use and associated adverse drug events in a pediatric emergency department. Pediatr Emerg Care. 2010 Jun;26(6):424-30. doi: 10.1097/PEC.0b013e3181e057e1.</citation>
    <PMID>20502385</PMID>
  </results_reference>
  <results_reference>
    <citation>Shah SS, Hall M, Goodman DM, Feuer P, Sharma V, Fargason C Jr, Hyman D, Jenkins K, White ML, Levy FH, Levin JE, Bertoch D, Slonim AD. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med. 2007 Mar;161(3):282-90. Erratum in: Arch Pediatr Adolesc Med. 2007 Jul;161(7):655.</citation>
    <PMID>17339510</PMID>
  </results_reference>
  <results_reference>
    <citation>de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. Vancomycin population pharmacokinetics in neonates. Clin Pharmacol Ther. 2000 Apr;67(4):360-7.</citation>
    <PMID>10801244</PMID>
  </results_reference>
  <results_reference>
    <citation>García B, Barcia E, Pérez F, Molina IT. Population pharmacokinetics of gentamicin in premature newborns. J Antimicrob Chemother. 2006 Aug;58(2):372-9. Epub 2006 Jun 16.</citation>
    <PMID>16782742</PMID>
  </results_reference>
  <results_reference>
    <citation>Wade KC, Wu D, Kaufman DA, Ward RM, Benjamin DK Jr, Sullivan JE, Ramey N, Jayaraman B, Hoppu K, Adamson PC, Gastonguay MR, Barrett JS; National Institute of Child Health and Development Pediatric Pharmacology Research Unit Network.. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother. 2008 Nov;52(11):4043-9. doi: 10.1128/AAC.00569-08. Epub 2008 Sep 22.</citation>
    <PMID>18809946</PMID>
  </results_reference>
  <results_reference>
    <citation>Capparelli E, Hochwald C, Rasmussen M, Parham A, Bradley J, Moya F. Population pharmacokinetics of cefepime in the neonate. Antimicrob Agents Chemother. 2005 Jul;49(7):2760-6.</citation>
    <PMID>15980347</PMID>
  </results_reference>
  <results_reference>
    <citation>Spooner N, Lad R, Barfield M. Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method. Anal Chem. 2009 Feb 15;81(4):1557-63. doi: 10.1021/ac8022839.</citation>
    <PMID>19154107</PMID>
  </results_reference>
  <results_reference>
    <citation>Cheung CY, van der Heijden J, Hoogtanders K, Christiaans M, Liu YL, Chan YH, Choi KS, van de Plas A, Shek CC, Chau KF, Li CS, van Hooff J, Stolk L. Dried blood spot measurement: application in tacrolimus monitoring using limited sampling strategy and abbreviated AUC estimation. Transpl Int. 2008 Feb;21(2):140-5. Epub 2007 Oct 17.</citation>
    <PMID>17944802</PMID>
  </results_reference>
  <results_reference>
    <citation>Allanson AL, Cotton MM, Tettey JN, Boyter AC. Determination of rifampicin in human plasma and blood spots by high performance liquid chromatography with UV detection: a potential method for therapeutic drug monitoring. J Pharm Biomed Anal. 2007 Aug 15;44(4):963-9. Epub 2007 Apr 19.</citation>
    <PMID>17531423</PMID>
  </results_reference>
  <results_reference>
    <citation>Hibberd SG, Alveyn C, Coombes EJ, Holgate ST. Acute and chronic pharmacokinetics of asymmetrical doses of slow release choline theophyllinate in asthma. Br J Clin Pharmacol. 1986 Sep;22(3):337-41.</citation>
    <PMID>3768245</PMID>
  </results_reference>
  <results_reference>
    <citation>Meyer DM, Jessen ME. Results of extracorporeal membrane oxygenation in children with sepsis. The Extracorporeal Life Support Organization. Ann Thorac Surg. 1997 Mar;63(3):756-61.</citation>
    <PMID>9066397</PMID>
  </results_reference>
  <results_reference>
    <citation>Green TP, Timmons OD, Fackler JC, Moler FW, Thompson AE, Sweeney MF. The impact of extracorporeal membrane oxygenation on survival in pediatric patients with acute respiratory failure. Pediatric Critical Care Study Group. Crit Care Med. 1996 Feb;24(2):323-9.</citation>
    <PMID>8605808</PMID>
  </results_reference>
  <results_reference>
    <citation>Cohen P, Collart L, Prober CG, Fischer AF, Blaschke TF. Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation. Pediatr Infect Dis J. 1990 Aug;9(8):562-6.</citation>
    <PMID>2122409</PMID>
  </results_reference>
  <results_reference>
    <citation>Amaker RD, DiPiro JT, Bhatia J. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 1996 May;40(5):1139-42.</citation>
    <PMID>8723454</PMID>
  </results_reference>
  <results_reference>
    <citation>Dagan O, Klein J, Bohn D, Koren G. Effects of extracorporeal membrane oxygenation on morphine pharmacokinetics in infants. Crit Care Med. 1994 Jul;22(7):1099-101.</citation>
    <PMID>8026197</PMID>
  </results_reference>
  <results_reference>
    <citation>Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006 Apr 5;295(13):1549-55.</citation>
    <PMID>16595758</PMID>
  </results_reference>
  <results_reference>
    <citation>Srinivasan V, Nadkarni VM, Helfaer MA, Carey SM, Berg RA; American Heart Association National Registry of Cardiopulmonary Resuscitation Investigators.. Childhood obesity and survival after in-hospital pediatric cardiopulmonary resuscitation. Pediatrics. 2010 Mar;125(3):e481-8. doi: 10.1542/peds.2009-1324. Epub 2010 Feb 22.</citation>
    <PMID>20176666</PMID>
  </results_reference>
  <results_reference>
    <citation>Winnike JH, Li Z, Wright FA, Macdonald JM, O'Connell TM, Watkins PB. Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin Pharmacol Ther. 2010 Jul;88(1):45-51. doi: 10.1038/clpt.2009.240. Epub 2010 Feb 24.</citation>
    <PMID>20182423</PMID>
  </results_reference>
  <results_reference>
    <citation>Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Lamba J, Bowman P, Burckart GJ. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol. 2002 Sep;63(9):765-70.</citation>
    <PMID>12175731</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>August 17, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University Medical Center</investigator_affiliation>
    <investigator_full_name>Daniel Benjamin</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>adenovirus</keyword>
  <keyword>adrenal insufficiency</keyword>
  <keyword>afterload inducer</keyword>
  <keyword>amnestic</keyword>
  <keyword>anaesthetic</keyword>
  <keyword>anesthesia</keyword>
  <keyword>angina</keyword>
  <keyword>anticoagulant</keyword>
  <keyword>anti-epileptic</keyword>
  <keyword>anti-inflammatory</keyword>
  <keyword>antimicrobial</keyword>
  <keyword>anti-psychotic</keyword>
  <keyword>antiviral</keyword>
  <keyword>anxiety</keyword>
  <keyword>anxiolysis</keyword>
  <keyword>anxiolytic</keyword>
  <keyword>autism</keyword>
  <keyword>autistic disorder</keyword>
  <keyword>benzodiazepine</keyword>
  <keyword>bipolar disorder</keyword>
  <keyword>convulsions</keyword>
  <keyword>edema</keyword>
  <keyword>epilepsy</keyword>
  <keyword>headaches</keyword>
  <keyword>herpes simplex virus</keyword>
  <keyword>HSV</keyword>
  <keyword>hypertension</keyword>
  <keyword>infantile hemangioma</keyword>
  <keyword>infection</keyword>
  <keyword>inflammation</keyword>
  <keyword>influenza</keyword>
  <keyword>LRTI</keyword>
  <keyword>meningitis</keyword>
  <keyword>migraines</keyword>
  <keyword>muscle spasms</keyword>
  <keyword>pain</keyword>
  <keyword>pneumonia</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>retinitis</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>sedation</keyword>
  <keyword>sedative</keyword>
  <keyword>seizures</keyword>
  <keyword>septicemia</keyword>
  <keyword>swelling</keyword>
  <keyword>thromboprophylaxis</keyword>
  <keyword>thrombosis</keyword>
  <keyword>urinary tract infection</keyword>
  <keyword>UTI</keyword>
  <keyword>withdrawal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Headache</mesh_term>
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Adenoviridae Infections</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Cytomegalovirus Retinitis</mesh_term>
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Intraabdominal Infections</mesh_term>
    <mesh_term>Adrenal Insufficiency</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Hemangioma, Capillary</mesh_term>
    <mesh_term>Port-Wine Stain</mesh_term>
    <mesh_term>Meningitis, Bacterial</mesh_term>
    <mesh_term>Spasm</mesh_term>
    <mesh_term>Central Nervous System Infections</mesh_term>
    <mesh_term>Brain Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydromorphone</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Completed study datasets (limited PHI) may be requested from https://pediatrictrials.org/data-sharing-opportunities</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
